Table of Contents
July 01, 2002; Volume 69, Issue 7-
From the Editor
-
We need your help
John D. Clough, MD and Peter G. Studer- Cleveland Clinic Journal of Medicine July 2002, 69 (7) 519;
If your copy of the Journal has a postcard on the cover, please sign it and drop it in the mail—it could save us a lot of money.
-
-
The Clinical Picture
-
A traveler with nonhealing skin nodules
Marc Williams, MD, John Kevin Hix, MD and Mikal Rahman, MD- Cleveland Clinic Journal of Medicine July 2002, 69 (7) 524-528;
Questions and answers on the visible signs of diseases.
-
-
Cancer Diagnosis and Management
-
Malignant melanoma: Treatments emerging, but early detection is still key
Maurie Markman, MD, Paul Masci, DO and Ernest C. Borden, MD- Cleveland Clinic Journal of Medicine July 2002, 69 (7) 529-545;
Interferon alfa-2b can increase disease-free survival in malignant melanoma, but we can have far more impact by detecting this disease earlier and by teaching patients how to recognize and possibly avoid it.
-
-
1-Minute Consult
-
Why shouldn’t we use warfarin alone to treat acute venous thrombosis?
Toni Choueiri, MD and Steven R. Deitcher, MD- Cleveland Clinic Journal of Medicine July 2002, 69 (7) 546-548;
Heparins produce desired levels of anticoagulation within hours, whereas warfarin takes at least 4 days.
-
-
Im Board Review
-
A 76-year-old man with septic arthritis
David L. Longworth, MD, James K. Stoller, MD, Prashanthi N. Thota, MD, Madhusudhan R. Sanaka, MD and Darwin L. Conwell, MD- Cleveland Clinic Journal of Medicine July 2002, 69 (7) 549-553;
What is the cause of this patient’s symptoms? A self-test.
-
-
Interpreting Key Trials
-
GUSTO V: Combination drug treatment of acute myocardial infarction
Arman T. Askari, MD and A. Michael Lincoff- Cleveland Clinic Journal of Medicine July 2002, 69 (7) 554-560;
The combination of abciximab in full doses and reteplase in half doses was not superior to full-dose reteplase alone, but it was “not inferior” either.
-
-
Commentary
-
GUSTO V: Should it affect clinical practice?
James L. Orford, MBCHB, MPH and Peter B. Berger, MD- Cleveland Clinic Journal of Medicine July 2002, 69 (7) 520-522;
The results of GUSTO V were equivocal and should not lead physicians to change how they treat myocardial infarction.
-
-
Current Drug Therapy
-
Aromatase inhibitors in breast cancer: Current and evolving roles
John Hill, MD and Halle Moore, MD- Cleveland Clinic Journal of Medicine July 2002, 69 (7) 561-567;
Aromatase inhibitors are finding new uses. Already established for treating metastatic breast cancer in postmenopausal women, they are gaining acceptance as adjuvant treatment as well.
-
-
Medical Grand Rounds
-
Acute renal failure in hospitalized patients
Joseph V. Nally Jr., MD- Cleveland Clinic Journal of Medicine July 2002, 69 (7) 569-574;
Acute renal failure demands a logical approach to its prevention and early diagnosis.
-
-
Departments
-
Coxibs supplement: Has CCJM sold out? (April 2002)
Emanuel Frisch, MD- Cleveland Clinic Journal of Medicine July 2002, 69 (7) 568;
-
In reply: Coxibs supplement: Has CCJM sold out? (April 2002)
Marc C. Hochberg, MD, MPH- Cleveland Clinic Journal of Medicine July 2002, 69 (7) 568;
-
In reply: Coxibs supplement: Has CCJM sold out? (April 2002)
John D. Clough, MD- Cleveland Clinic Journal of Medicine July 2002, 69 (7) 568;
-
Hereditary hemochromatosis
- Cleveland Clinic Journal of Medicine July 2002, 69 (7) 553;
Hereditary hemochromatosis (Cleve Clin J Med 2002; 69:224–237).
-
